同仁堂医养通过港交所聆讯，中医医疗服务营收占比约八成

智通财经2025-10-01

据港交所9月30日披露，北京同仁堂（600085）医养投资股份有限公司(简称：同仁堂医养)通过港交所主板上市聆讯，中金公司（601995）为其独家保荐人。据招股书，同仁堂医养是同仁堂旗下一家战略性聚焦于中国中医医疗服务的附属公司，专注于为个人客户提供全面中医医疗服务，为机构客户提供标准化管理服务，并提供各种医药产品及其他产品。公司将“医”与“养”相结合，提供现代化、定制化的中医医疗服务。截至...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2572861345?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-01 14:21","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2572861345","market":"hk","top_or_hot":-1,"title":"同仁堂医养通过港交所聆讯，中医医疗服务营收占比约八成","media":"智通财经","content":"<div>\n<p>据港交所9月30日披露，北京同仁堂（600085）医养投资股份有限公司(简称：同仁堂医养)通过港交所主板上市聆讯，中金公司（601995）为其独家保荐人。据招股书，同仁堂医养是同仁堂旗下一家战略性聚焦于中国中医医疗服务的附属公司，专注于为个人客户提供全面中医医疗服务，为机构客户提供标准化管理服务，并提供各种医药产品及其他产品。公司将“医”与“养”相结合，提供现代化、定制化的中医医疗服务。截至...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001142349a6a99e71&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>同仁堂医养通过港交所聆讯，中医医疗服务营收占比约八成</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n同仁堂医养通过港交所聆讯，中医医疗服务营收占比约八成\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-01 14:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001142349a6a99e71&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>据港交所9月30日披露，北京同仁堂（600085）医养投资股份有限公司(简称：同仁堂医养)通过港交所主板上市聆讯，中金公司（601995）为其独家保荐人。据招股书，同仁堂医养是同仁堂旗下一家战略性聚焦于中国中医医疗服务的附属公司，专注于为个人客户提供全面中医医疗服务，为机构客户提供标准化管理服务，并提供各种医药产品及其他产品。公司将“医”与“养”相结合，提供现代化、定制化的中医医疗服务。截至...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001142349a6a99e71&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1211504680.USD","symbol_name":"ALLIANZ HIGH DIVIDEND ASIA PACIFIC EQUITY \"AM\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001142349a6a99e71&s=b","article_id":"2572861345","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001142349a6a99e71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2572861345","pubTimestamp":1759299684,"columns":[{"name":"聆讯消息","id":19,"label_key":null}],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据港交所9月30日披露，北京同仁堂（600085）医养投资股份有限公司(简称：同仁堂医养)通过港交所主板上市聆讯，中金公司（601995）为其独家保荐人。据招股书，同仁堂医养是同仁堂旗下一家战略性聚焦","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1211504680.USD":"ALLIANZ HIGH DIVIDEND ASIA PACIFIC EQUITY \"AM\" (USD) INC","LU1105468828.SGD":"Allianz Total Return Asian Equity AM DIS H2-SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","02667":"同仁堂医养","LU0918141705.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AM\" (HKD) INC","LU0648948544.HKD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AM\" (HKD) INC","LU1282649067.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AMG\" (USD) INC A","IE00BKZH1Z71.USD":"BNY MELLON ASIAN INCOME \"B\" (USD) ACC","LU1282649810.SGD":"Allianz Asian Multi Income Plus Cl AMg DIS H2-SGD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","SGXZ90724238.SGD":"UNITED ASIA \"A\" (SGD) INC","LU0149534421.HKD":"SCHRODER ISF HONG KONG EQ \"A\" ACC","LU0762540952.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AC\" (USD) ACC","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","LU0197773673.USD":"HSBC GIF ASIA PACIF EX JAPAN EQ HD \"AS\" (USD) INC","LU0348816934.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (USD)","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","SG9999001846.SGD":"Schroder Asian Equity Yield A Dis SGD","LU0607220059.USD":"SCHRODER ISF HONG KONG EQUITY \"A\" (USD) ACC","LU0831103253.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1051769294.HKD":"BGF EMERGING MARKETS EQUITY INCOME \"A6\"(HKDHDG) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU2226246903.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT4\" (HKD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1366334651.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"I\" (USD) INC","LU1048588211.SGD":"Blackrock Asian Dragon A2 SGD-H","LU0577902454.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) ACC","LU0886674414.USD":"CT (LUX) I ASIAN EQUITY INCOME \"AUP\" (USD) INC","BK1610":"ETF&股票定投概念","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU0072462343.USD":"贝莱德亚洲巨龙基金","LU0594300419.USD":"富达中国消费基金A","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0898667661.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD-H","LU0650527681.SGD":"Fidelity China Consumer A-SGD","SG9999001051.SGD":"United Asia Fund SGD","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU2257852520.SGD":"JPMorgan Funds - Asia Growth A (acc) SGD"},"translate_title":"Tong Ren Tang Medical Care passed the hearing of the Hong Kong Stock Exchange, and the revenue of Chinese medicine medical services accounted for about 80%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02667":2},"content_text":"据港交所9月30日披露，北京同仁堂（600085）医养投资股份有限公司(简称：同仁堂医养)通过港交所主板上市聆讯，中金公司（601995）为其独家保荐人。据招股书，同仁堂医养是同仁堂旗下一家战略性聚焦于中国中医医疗服务的附属公司，专注于为个人客户提供全面中医医疗服务，为机构客户提供标准化管理服务，并提供各种医药产品及其他产品。公司将“医”与“养”相结合，提供现代化、定制化的中医医疗服务。截至2025年9月23日，公司已建立分级中医医疗服务网络，包括12家自有线下医疗机构及一家互联网医院，以及10家线下管理医疗机构。依托知名品牌“同仁堂”及优质的药品，公司已积累及整合大量线上线下（300959）医疗资源。按2024年总门诊人次及住院人次计，公司是中国非公立中医院医疗服务行业中最大的中医院集团，市场份额为1.7%。按2024年医疗服务总收入计，公司以0.2%的市场份额在非公立中医院医疗服务行业中排名第二，其市场规模占同年中国中医医疗服务行业市场总规模的46.5%。于往绩记录期间，公司的收入主要来自中医医疗服务；管理服务；销售健康产品及其他产品。从收入贡献上来看，中医医疗服务产生的收入由截至2022年12月31日止年度的人民币8.15亿元增加22.1%至截至2023年12月31日止年度的人民币9.95亿元；管理服务的收入由截至2022年12月31日止年度的人民币190万元大幅增加至截至2023年12月31日止年度的人民币960万元；销售健康产品及其他产品的收入由截至2022年12月31日止年度的人民币8770万元增加57.0%至截至2023年12月31日止年度的人民币1.38亿元。同仁堂医养指，同仁堂集团的其他上市成员公司亦提供有限的中医医疗服务，但本集团集中于提供中医医疗服务的主要业务活动不同，公司同系附属公司通过坐堂中医医师提供的中医医疗服务主要作为其药物零售业务的补充，在经营规模、业务定位、服务范围或目标客户群等方面与公司的中医医疗服务存在差异。控股股东上，公司的最终控股股东同仁堂有权直接及间接通过同仁堂康养、同仁堂传承基金管理、同仁堂医疗基金管理、同仁堂养老基金、同康基金及同清基金行使已发行股本总额约93.83%的投票权。招股书提示，公司的业务运营主要集中于中医领域，中医在中国的接受程度可能会发生变化，而公司的业务、财务状况及经营业绩可能会受到重大影响。此外，公司可能无法维持或续期“同仁堂”商标许可使用及授权及/或从同仁堂租赁的物业。业绩方面，于2022年度、2023年度、2024年度及2025年截至5月31日止五个月，同仁堂医养实现收入分别约为9.11亿元、11.53亿元、11.75亿元、4.77亿元人民币；同期，期内利润分别为-923.3万元、4263.4万元、4619.7万元、1306.2万元人民币。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2572861345","isCrawlerRequest":true}